Center on Health Equity & Access

High area level housing cost burden is associated with increased cardiovascular hospitalizations and emergency department use among Medicaid beneficiaries.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Low-cost, scalable interventions can improve first-fill adherence, reduce avoidable hospitalizations, and support patient-centered strategies.

Employers use carve-outs and cash-pay channels to reduce GLP-1 costs, while Scripta’s Navigator helps members compare prices and find support.

Nurse understaffing linked to higher in-hospital mortality, 30-day readmissions, and longer stays.

New data show Chicago’s South Side Level 1 trauma center cuts gunshot travel times and lowers firearm deaths, highlighting equity gains.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

Over 15,000 NYC nurses ratified new contracts after a 41-day strike, securing staffing protections, salary increases, and safety reforms.

Mark Meiselbach, PhD, at Johns Hopkins, explains Medicare Advantage market corrections, Star Rating System pressures, and rural plan exits.

As utilization of GLP-1s grows for diabetes and weight management, out-of-pocket expenses and affordability concerns may affect broader health care policy discussions.

MA grocery card use was associated with modest increases in wellness, primary care, and specialist visits among dual-eligible beneficiaries, says Jennifer L. Kowalski, MS.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

New GLP-1 pills challenge injections as competition, and discussions of possible Medicare coverage could push prices down.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Phase 2 trial finds 5-day preoperative RT in high-risk STS shows comparable wound complication rates and acceptable toxicity.

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health access and outcomes.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

The number of brick and mortar abortion clinics in the US fell between 2024 and 2025, with notable closures even in states considered key access points.

Learn what sickle cell disease is, who it affects most, today’s treatment options, and how cost and inequities limit access.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Advances in sickle cell therapies, including gene editing, offer hope—but racial disparities, cost, and access barriers remain major challenges.